Compare Norfolk Southern Corporation (NSC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs TG Therapeutics Inc — how do they compare? Norfolk Southern Corporation trades at $333.48 (market cap $75.23B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: Norfolk Southern Corporation is far larger — about 9.1× TG Therapeutics Inc's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NSC | TGTX | |
|---|---|---|
Market Cap | $75.23B | $8.26B |
Sector | Technology | Health |
52-Week High | $340.16 | $59.06 |
52-Week Low | $272.35 | $26.39 |
Enterprise Value | $90.99B | $8.50B |
Dividend Yield | 1.61% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
